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Malaria Division. Medical Department. Tanganyika.
Drugs used for the prophylaxis of malaria are 
generally recommended in doses sufficient to 
suppress the disease in persons without immunity, 
these amounts being considerably in excess of 
those required for the protection of indigenous 
inhabitants of malarious districts. Information 
is not generally available concerning the smallest 
useful doses of the 4-aminoquinoline series of 
suppressives amongst school children who pos­
sess a high degree of premunition, because 
treatment varies from place to place in relation 
to differing degrees of immunity and infection 
risk.
It is the purpose of the trials described in this 
report to demonstrate dosages of amodiaquine 
and chloroquine just sufficient to prevent overt 
parasitaemia in children aged 6 to 15 years 
native to areas of holoendemic malaria trans­
mission in East and Central Africa where Plas­
modium falciparum predominates.
Method: The Subjects and the Drugs
Apparently healthy African children attend­
ing three schools near Muheza, in north-east 
Tanganyika, were treated at the commencement 
of this investigation with a single large dose of 
the appropriate 4-aminoquinoline in order to 
remove existing parasitaemia. Four days later 
the first of the prophylactic treatments was 
administered, some of the children being ex­
cluded for purposes of contrast. The children 
lived in an area of malarial holoendemicity 
described previously by Davidson and Draper 
(19551, the relevant parasite rates found by 
ourselves being:
Parasite
Age Rate
n— 2 ............. .......................  76
3— 5 ............. .......................  88
6—10 ............. .......................  82
11—15 ............. .......................  63
Adult ............. .......................  24
The most prevalent species, Plasmodium fulci- 
parum, was present in 98 per cent, of positive 
slides of children aged 6 to 15. P. malariae in 
4 per cent, and P. vivax in 1 per cent.
The drug dosage used for initial parasite 
suppression was 0.6 gm. amodiaquine or chloro­
quine base, adult dose, modified according to the 
age of the child. Following this treatment, the 
blood was cleared of parasites. In the unpro­
tected control cases parasitaemia recurred within 
eight weeks. The remaining children received, 
under our direct supervision, the prophylactic 
doses divided into four schedules for each of
Table I
P rophylactic T rials with Amodiaquine at Two-Week Intervals
Schedule Age 6-8 Age 9-10 Age 11-12 Age 13-15
A l: dose (gm. base) ....................... 0.15 0.15 0.2 0.25
Number examined ............. 8 21 17 20
Number reinfected ............. 0 1 0 0
A2: dose ........................................... 0.1 0.1 0.15 0.2
Number examined ............. 25 30 26 15
Number reinfected ............. 0 0 0 0
A3: dose ........................................... 0.05 0.05 0.1 0.1
Number examined ............. 27 35 36 19
Number reinfected 7 6 0 0
A4: dose .......... 0.025 0.025 0.05 0.05
Number examined 15 13 27 20
Number reinfected 8 6 2 1
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the two drugs. These schedules were calculated 
from the adult dose using Young’s formula, to 
the nearest one-eighth tablet, powdering not 
being practicable on account of bitterness. Blood 
examinations were limited to the untreated child­
ren and to those receiving the drugs fortnightly, 
for a period of 8 to 12 weeks without defaulting, 
and were made at the end of a two-week period.
Results ok Fortnightly Drug Prophylaxis
Amodiaquine.—Four graduated schedules of 
dosage of amodiaquine were used. The first, 
Al, corresponding to 0.4 gm. adult dose, was 
related to that recommended by Coveil, Coatney, 
Field and Jaswant Singh (1955) for non-im- 
mune subjects, but was given at intervals of two 
weeks. The schedules A2, A3 and A4 were 
progressively less, corresponding to adult doses 
of 0.3, 0.2 and 0.1 gm. The dosages and the 
results of blood examinations performed follow­
ing 8 to 12 weeks of treatment are shown in 
Table 1.
It appears from Table 1 that under the con­
ditions of premunition existing amongst the 
school children, and following upon clearance 
of blood parasites, amodiaquine at a fortnightly 
dosage of 0.1 gm. was sufficient to prevent re­
currence of parasitaemia despite the high rate 
of transmission prevailing.
Chloroquine.—Four schedules of dosage of 
chloroquine diphosphate were also used, the 
first, Cl, corresponding to 0.3 gm. base adult 
dose, being that recommended for non-immunes, 
but administered at fortnightly intervals. The 
schedules C2, C3 and C4 corresponded to adult 
doses of 0.225, 0.15 and 0.075 gm. respectively. 
The dosages expressed as chloroquine base, for 
three-quarter, quarter and one-eighth tablets re­
duced to two decimal places, are shown in 
Table II.
These results for chloroquine indicate that a 
fortnightly dosage of 0.075 gm. base prevented 
a recurrence of parasitaemia following initial 
blood clearance.
P arasite Densities
Al the largest dosages through which parasites 
reappeared the densities remained in most cases 
low, less than 100 per c.m. blood, irrespective 
of age of child. Many of these parasites were 
damaged. At the next lower schedule densities 
were considerably higher and parasites stained 
normally in films from younger and less immune 
children. All the positive slides contained /'. 
falciparum and two also were seen to have
P. mulariae, these latter being at the lowest 
chloroquine dosage in children aged 8 to 10.
The single case of break-through on the 
highest amodiaquine schedule could not be ex­
plained, but was in such low density that only 
one asexual ring was found. The child con­
cerned was a lifelong resident of the district 
and differed in immunity in no manner from 
his fellows.
Discussion
The amount of amodiaquine found by our­
selves to be just sufficient to prevent parasitaemia, 
0.1 gm. given once every two weeks, may be 
compared with the findings of other workers. 
Authors in India and Malaya have recorded 
amodiaquine dosages of 0.4 gm. administered 
fortnightly as being suitable for indigenous 
children living in endemic districts, for one group 
aged less than 12 years half that amount offering 
considerable protection. In Africa, Fabre and 
Joigny (1955) in French Equatoria have found, 
for amodiaquine in highly endemic areas, 0.4 
gm. suitable at intervals of two weeks in the 
prophylaxis of malaria in children aged 6 to 
12; and de Smet (1952) has given monthly 
treatments in the Belgian Congo at the rate of 
25 mg. per kilo, body weight to children aged 
up to 12 years, this being from three to five 
times the minimal protective dose recorded by 
ourselves. At weekly intervals Miller (1954) 
in Liberia found 0.2 gm. effective in children 
aged 6 to 14, although an occasional temporary 
break-through took place.
The amount of chloroquine, 0.075 gm., used 
by us every two weeks may also be compared. 
Doucet (1947) found in the Congo in areas of 
high endemicity, 0.125 gm. weekly was com­
pletely protective for children aged six to seven; 
and Rule (1951), using weekly doses of the 
diphosphate following initial eradication therapy, 
recommended for the effective suppression of 
malaria 0.25 gm. (one tablet) in children aged 
less than 10 years, and 0.375 gm. in those from 
10 to 15. These doses appear, however, to have 
been expressed not in base but in salt, and 
should probably read 0.15 and 0.225 gm. base 
respectively. Also Miller (1954) used 0.15 gm. 
base chloroquine al weekly rates with effective 
suppression of malaria in children aged 6 to 14.
It therefore appears, following initial blood 
clearance, that the quantities of the two drugs 
found by ourselves to prevent recurrence of 
parasitaemia are from one-half to one-quarter 
those recommended elsewhere for school child-
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Table II
Prophylactic: Trials with Chloroquine at Two-Week Intervals
Schedule Age 6-8 Age 9-10 Age 11-12 Age 13-15
C l: dose (gm. base) ....................... 0.11 0.11 0.15 0.19
Number examined ............. 19 23 22 17
Number reinfected ............. 0 0 0 0
C2: dose 0.075 0.075 0.11 0.15
Number examined ............. 27 22 33 32
Number reinfected ............. 0 0 0 0
(3 : dose ........................................... 0.04 0.04 0.075 0.075
Number examined ............. 30 46 35 33
Number reinfected ............. 6 4 0 0
C4: dose ........................................... 0.02 0.02 0.04 0.04
Number examined ............. 17 26 31 26
Number reinfected ............. 8 9 8 2
ren native to districts where malaria is endemic 
and the inhabitants semi-immune. It appears 
likely, moreover, that the initial blood clearance 
treatment is unnecessary, the prophylactic doses 
themselves sufficing to clear parasites. Margin­
ally effective dosages such as these are obviously 
insufficient for the protection of non-immune 
subjects, although with the 4-aminoquinolines 
the hazard of drug resistance need not be feared. 
The most serious objection to the use of any 
fortnightly treatment is that, in the event of a 
dose being missed, parasitaemia may ensue 
before the next dose falls due; on praetical 
grounds, therefore, the weekly administration of 
0.1 gm. amodiaquine or 0.075 gm. chloroquine 
base to semi-immune children is preferable.
Summary
An investigation is reported concerning the 
smallest effective prophylactic doses of 4-amino­
quinolines used amongst African school children 
aged 6 to 15 years native to areas of malarial
holoendemicity in Tanganyika. Fortnightly 
doses of 0.1 gm. amodiaquine and 0.075 gm. 
base chloroquine prevented recurrence of para­
sitaemia over a period of 8 to 12 weeks.
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